Fulphila 10 mg (Pegfilgrastim SOLUTION) 10 MG

FULPHILA 10 MG is a subcutaneous solution containing pegfilgrastim, used to support the immune system during certain medical treatments. This biosimilar medication helps stimulate the production of white blood cells.

Strength

10 MG

Manufacturer / TM Owner

BIOSIMILAR COLLABORATIONS IRELAND LIMITED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

FULPHILA 10 MG is primarily used to reduce the risk of infection in patients undergoing chemotherapy. It works by stimulating the bone marrow to produce more white blood cells, which are crucial for fighting infections. This medication is often prescribed to support the immune system during cancer treatments.

Side Effects

Common effects of FULPHILA 10 MG may include bone pain, headache, and fatigue. Some users might experience mild swelling or redness at the injection site. These effects are generally temporary and should subside as the body adjusts to the medication.

Precautions & Warnings

FULPHILA 10 MG should be handled with care and stored as directed. It is important to follow the healthcare provider's instructions for administration. Patients should inform their healthcare provider about any allergies or medical conditions before using this medication.

Avoid Interactions

FULPHILA 10 MG may interact with other medications, including those that affect the immune system. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements may also affect the efficacy of this medication.

Frequently Asked Questions

FULPHILA 10 MG is used to support the immune system in patients undergoing chemotherapy by stimulating the production of white blood cells.

FULPHILA 10 MG is administered via subcutaneous injection, typically by a healthcare professional.

Common side effects may include bone pain, headache, and fatigue. Some users might also experience mild swelling or redness at the injection site.

It is important to discuss all current medications with a healthcare provider to avoid potential interactions with FULPHILA 10 MG.

Patients should inform their healthcare provider about any allergies or medical conditions before using FULPHILA 10 MG and follow the provider's instructions for administration.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.